top of page
Biosciences
Offspring
Insights & Updates
De-Risking Synucleinopathy Therapeutics: A Human Tissue-First Framework for Target Validation
The transition from preclinical promise to clinical efficacy, the so-called "Translational Gap", remains the most perilous stage of drug development. Nowhere is this chasm wider than in neurodegeneration, where billions of dollars and years of research are lost when promising candidates fail in late-stage trials. The fundamental reason is often a stark divergence between the simplified environments of preclinical models and the complex, heterogeneous reality of human disease.
Featured
Search
Offspring Biosciences in research collaboration developing alpha-synuclein PET ligand
New publication, “Identification and in vitro characterization of C05-01, a PBB3 derivative with improved affinity for alpha-synuclein” together with Karolinska Institutet, Andrea Varrone research group. The approach used in this study also shows that TMAs are a useful tool for the evaluation of ligands in tissue from different proteinopathies, using both fluorescence and autoradiographic assays https://doi.org/10.1016/j.brainres.2020.147131 The neuropathological hallmark o
-
Sep 16, 20211 min read
Developing a new drug is a long and costly process with many pitfalls
Most projects are closed down before the drug has reached the market. With the support of Offspring Bioscience's unique expertise in tissue analysis, pharmaceutical companies significantly improve the odds of success "Our unique ability to plan and carry out such analyses is based on the experience we have built up over a long period of time through our work on pharmaceutical projects in the pharmaceutical industry. With efficient methods and refined analytical techniques,
-
Sep 16, 20211 min read
Our new innovative tissue staining platform turns complexity into simplicity
Offspring Biosciences is pleased to announce our expanded technical capacity with the purchase and installment of a Roche/Ventana Discovery Ultra tissue staining platform which significantly enhances our ability to deliver highly reliable, informative and 7-Plex Multiplex IHC & ISH Services | Preclinical CRO | Offspring Bioefficient support to our customers The Discovery Ultra platform allows for parallel and fully individualized processing of up to 30 slide-mounted tissue
-
Sep 16, 20211 min read
bottom of page